Citation

  • Authors: Qin, W., Shi, Y., Zhao, B., Yao, C., Jin, L., Ma, J., Jin, Y.
  • Year: 2010
  • Journal: PLoS One 5 e9429
  • Applications: in vitro / antimiR, mimic miRNA / INTERFERin
  • Cell types:
    1. Name: DU 145
      Description: Human prostate carcinoma cells
    2. Name: HEK-293T
      Description: Human embryonic kidney Fibroblast
      Known as: HEK293T, 293T
    3. Name: HeLa
      Description: Human cervix epitheloid carcinoma cells
    4. Name: HGC-27
      Description: Human stomach carcinoma, undifferenciated
      Known as: HGC27
    5. Name: MGC-803
      Description: Human gastric carcinoma
      Known as: MGC803

Method

20 to100 nM mimic miRNA and LNA-labeled oligoribonucleotides were transfected using INTERFERin.

Abstract

BACKGROUND: microRNAs (miRNAs) are small noncoding RNAs that regulate cognate mRNAs at the post-transcriptional stage. Several studies have shown that miRNAs modulate gene expression in mammalian cells by base pairing to complementary sites in the 3'-untranslated region (3'-UTR) of the target mRNAs. METHODOLOGY/PRINCIPAL FINDINGS: In the present study, miR-24 was found to target fas associated factor 1(FAF1) by binding to its amino acid coding sequence (CDS) region, thereby regulating apoptosis in DU-145 cells. This result supports an augmented model whereby animal miRNAs can exercise their effects through binding to the CDS region of the target mRNA. Transfection of miR-24 antisense oligonucleotide (miR-24-ASO) also induced apoptosis in HGC-27, MGC-803 and HeLa cells. CONCLUSIONS/SIGNIFICANCE: We found that miR-24 regulates apoptosis by targeting FAF1 in cancer cells. These findings suggest that miR-24 could be an effective drug target for treatment of hormone-insensitive prostate cancer or other types of cancers. Future work may further develop miR-24 for therapeutic applications in cancer biology.

Go to